Abstract
Background Multiple sclerosis (MS) disease-modifying treatments (DMTs) are tested in patients pre-selected for favorable risk/benefits ratios but prescribed broadly in clinical practice. We aimed to establish data-driven computations of individualized risk/benefit ratios to optimize MS care.
Methods We derived determinants of DMTs efficacy on disability progression from re-analysis and integration of 61 randomized, blinded Phase 2b/3 clinical trials that studied 46,611 patients for 91,787 patient-years. From each arm we extracted 80 and computed 30 features to identify and adjust for biases, and to use in multiple regression models. DMTs mortality risks were estimated from age mortality tables modified by published hazard ratios.
Findings Baseline characteristics of the recruited patients determine disability progression rates and DMTs efficacies with high effect sizes. DMTs efficacies increase with MS lesional activity (LA) measured by relapses or contrast-enhancing lesions and decrease with increasing age, disease duration and disability. Unexpectedly, as placebo arms’ relapse rate rapidly declines with trial duration, efficacy of MS DMTs likewise decreases quickly with treatment duration. Conversely, DMTs morbidity/mortality risks increase with age, advanced disability, and comorbidities. We integrated these results into an interactive personalized web based DMTs risk/benefit estimator.
Interpretation Results predict that prescribing DMTs to patients traditionally excluded from MS clinical trials causes more harm than benefit. Treatment with high efficacy drugs at MS onset followed by de-escalation to DMTs that do not increase infectious risks would optimize risk/benefit. DMTs targeting mechanisms of progression independent of LA are greatly needed as current DMTs inhibit disability caused by LA only.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been supported by the intramural research programs of the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Neurological Disorders and Stroke (NINDS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data there were originally published in Pubmed - URL for the studies are available in supplementary files
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data that supports the findings of this study are available in the supplementary material of this article.
Abbreviations and glossary terms
- A-CDP
- Annualized confirmed disability progression (proportion of subjects reaching A-CDP per each year of trial)
- A-CDP%Δ
- Efficacy on the annualized confirmed disability progression – because it measures difference in A-CDP between treated and untreated subject(s), higher efficacy is reflected by lower numbers
- A-CDP%Δ*TD
- Efficacy on annualized confirmed disability progression modified by time delay (TD) variable. Unless the drug prevents disability progression in all treated patients, this efficacy is always smaller than A-CDP%Δ because it does not assume that people who did not progress during trial duration will never progress; instead it assumed that MS drugs on average only delay, rather than completely prevent disability progression. TD variable computes the amount of this delay from published Kaplan-Meier survival curves. This is more realistic efficacy outcome than A-CDP%Δ
- ARR
- Annualized relapse rate (number of relapses per year)
- CEL#
- Number of contrast enhancing MS lesions on brain MRI
- DD
- MS duration. Calculated in years from first MS symptom
- DMTs
- disease modifying therapies
- LA
- Lesional activity. This term encompasses formation of new MS lesions, measured as contrast-enhancing lesions (CEL) or new T2 lesions and clinically represented by MS relapses
- MS
- multiple sclerosis
- PILA
- Progression independent of MS LA. Identifies patients with sustained disability progression who neither experience relapses nor form new or contrast enhancing MS lesions
- PIRA
- Progression independent of relapse activity. Identifies patients with sustained disability progression without MS relapses. These people may still have contrast enhancing lesions on brain and spinal cord MRI
- PPMS
- Primary progressive MS. Patients who never experienced MS relapses and are progressing. They can form contrast enhancing lesions on MRI of brain or spinal cord
- Progressive MS
- all patient who are progressing outside of relapse activity (PPMS+SPMS)
- RRMS
- Relapsing remitting MS. Patients who are experiencing MS relapses
- Relapse onset MS
- all MS patients who experience or experienced MS relapse (RRMS + SPMS)
- Residual variance
- statistical term that reflects imprecision of the model’s prediction. If model predicts outcome with 100% accuracy, the residual variance is zero. Residual variance may represent noise, or the proportion of the outcome that is determined by the predictor that is not available (e.g., unknown or not measured).
- SPMS
- Secondary progressive MS. Patients who experience relapses or experienced relapses at MS onset, but are now progressing between relapses or without relapses
- Stepwise multiple regression model
- statistical prediction of continuous outcome (such as probability of annualized confirmed disability progression) from multiple predictors. Selection of predictors occurs in stepwise fashion and is guided by statistical significance that reflects the probability that including the predictor makes outcome prediction meaningfully stronger
- SSW
- Supplementary Statistical Workbook
- TD
- time delay variable derived from published Kaplan-Meier survival curves. It reflects the yearly delay of disability progression and varies from 0-1, with 0 representing no delay and 1 representing full year.
